Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

VIVUS Inc (NASDAQ:VVUS)

1.13
Delayed Data
As of Sep 29
 -0.04 / -3.42%
Today’s Change
0.92
Today|||52-Week Range
2.25
+10.78%
Year-to-Date
Summit (SMMT): Rare Pediatric Disease Status for DMD Drug
Sep 28 / Zacks.com - Paid Partner Content
Endo Appoints New CEO, Keeps Q3 & '16 View, Stock Jumps
Sep 26 / Zacks.com - Paid Partner Content
Myriad Genetics to Present myRisk Data at Seattle Conference
Sep 28 / Zacks.com - Paid Partner Content
Teva Reports Positive Phase III Tardive Dyskinesia Data
Sep 23 / Zacks.com - Paid Partner Content
GW Pharma Attains 52-Week High on Positive Epidiolex Data
Sep 27 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close1.17
Today’s open1.16
Day’s range1.12 - 1.18
Volume463,451
Average volume (3 months)543,045
Market cap$121.9M
Dividend yield--
Data as of 09/29/2016

Growth & Valuation

Earnings growth (last year)-12.50%
Earnings growth (this year)+18.52%
Earnings growth (next 5 years)+0.84%
Revenue growth (last year)-16.42%
P/E ratioNM
Price/Sales1.11
Price/Book--

Competitors

 Today’s
change
Today’s
% change
MSLIMerus Labs Internati...-0.02-1.96%
TTNPTitan Pharmaceutical...-0.14-2.39%
ZYNEZynerba Pharmaceutic...-0.71-5.24%
AKAOAchaogen Inc+0.15+3.40%
Data as of 09/29/2016

Financials

Next reporting dateNovember 1, 2016
EPS forecast (this quarter)-$0.23
Annual revenue (last year)$95.4M
Annual profit (last year)-$93.1M
Net profit margin-97.57%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
Chief Executive Officer &
Director
Seth H. Z. Fischer
Chief Financial &
Accounting Officer
Mark K. Oki
Corporate headquarters
Mountain View, California

Forecasts

Search for Jobs